Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(CSE: MDMA )

0.2800 -0.0450 (-13.85%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 613,486
Open 0.3300
Bid (Size) 0.2800 (2,500)
Ask (Size) 0.2950 (2,500)
Prev. Close 0.3250
Today's Range 0.2800 - 0.3300
52wk Range 0.0650 - 0.3500
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
From PharmAla Biotech
Via GlobeNewswire
PharmAla Launches MDMA Clinical Trial Tool for Researchers
From PharmAla Biotech
Via GlobeNewswire

Performance

YTD
+86.67%
+86.67%
1 Month
+55.56%
+55.56%
3 Month
+180.00%
+180.00%
6 Month
+47.37%
+47.37%
1 Year
+166.67%
+166.67%

More News

Read More
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
From PharmAla Biotech
Via GlobeNewswire
Canadian Biotech Duo Hits Psilocybin Extraction Milestone For API Development At Scale
Via Benzinga
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
From PharmAla Biotech
Via GlobeNewswire
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
From PharmAla Biotech
Via GlobeNewswire
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
From PharmAla Biotech
Via GlobeNewswire
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
From PharmAla Biotech
Via GlobeNewswire
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing
From PharmAla Biotech
Via GlobeNewswire
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
From PharmAla Biotech
Via GlobeNewswire
PharmAla Begins Trading on OTCQB
From PharmAla Biotech
Via GlobeNewswire
PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
From PharmAla Biotech
Via GlobeNewswire
Life Science Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Investor Forum Agenda Announced for June 22nd
From Virtual Investor Conferences
Via GlobeNewswire
USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
From PharmAla Biotech
Via GlobeNewswire
PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health
From PharmAla Biotech
Via GlobeNewswire
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change
From PharmAla Biotech
Via GlobeNewswire
The Power Play by The Market Herald Releases New Interviews with Pharmala Biotech Holdings, Nextech AR Solutions and Enertopia Discussing Their Latest News
Via ACCESSWIRE
KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
PharmAla Completes Pre-IND Meeting with FDA, to Present at KCSA Virtual Investor Conference
From Virtual Investor Conferences
Via GlobeNewswire
KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th
From Virtual Investor Conferences
Via GlobeNewswire
Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement
From PharmAla Biotech
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.